Peter Hammerman

Peter Hammerman

Company: Novartis

Job title: Global Head of Translational Oncology

Seminars:

Combination Therapies with SHP2 Inhibitors to Treat KRAS Mutant Cancers 10:00 am

• Exploring the potential of SHP2i & G12Ci combination for KRAS G12C mutant cancers • Benchmarking the effectivity of combining SHP2i & MAPKi to target KRAS mutant cancers • Adopting CDK4/6i within combination for effective KRAS therapy combination approach for effective KRAS therapyRead more

day: Day Two

Panel Discussion: Empowering Combination Strategies to Target RAS Mutant Cancers: The Future of Oncology Therapy 4:30 pm

What are the key factors to consider ensuring successful translation from discovery to clinic? The importance of moving beyond G12C – with the abundance of research surrounding G12C mutation, how and why should we be pushing for new avenues to explore? Technology, platforms & collaborations – what does the RAS community need in order to…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.